methyl 3-[1H-imidazol-4-yl]propenoate hydrochloride salt | 52838-22-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: methyl 3-[1H-imidazol-4-yl]propenoate hydrochloride salt
• 英文别名: Methyl 3-(imidazol-4-yl)acrylate hydrochloride；methyl 3-(1H-imidazol-5-yl)prop-2-enoate;hydrochloride
• CAS: 52838-22-9
• 化学式: C₇H₈N₂O₂*ClH
• 分子量: 188.614
• InChiKey: ZCBDROJOIVNJSB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.02
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  55
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 3-[1H-imidazol-4-yl]propenoate hydrochloride salt 在 palladium 10% on activated carbon 、 氢气 、 sodium hydride 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 28.0h， 生成 methyl 3-(1-methyl-1H-imidazol-4-yl)propanoate
  参考文献：
  名称：

  Facile Syntheses of Histamine- and Imidazole-4-propionic Acid–Derived Room-Temperature Ionic Liquids

  摘要：

  We report synthesis of histamine- and imidazole-4-propionic acid-based ionic liquids containing a variety of alkyl and aryl groups placed at the two different positions of the constituent imidazole ring in convenient steps in good yields.

  DOI：

  10.1080/00397911.2011.555053
• 作为产物：
  描述：

  甲醇 、 尿刊酸 在 盐酸 作用下， 反应 2.0h， 以87%的产率得到methyl 3-[1H-imidazol-4-yl]propenoate hydrochloride salt
  参考文献：
  名称：

  Facile Syntheses of Histamine- and Imidazole-4-propionic Acid–Derived Room-Temperature Ionic Liquids

  摘要：

  We report synthesis of histamine- and imidazole-4-propionic acid-based ionic liquids containing a variety of alkyl and aryl groups placed at the two different positions of the constituent imidazole ring in convenient steps in good yields.

  DOI：

  10.1080/00397911.2011.555053

文献信息

• 1H-4(5)-substituted imidazole derivatives, their preparation and their use as histamine H3 receptor ligands
  申请人：James Black Foundation Limited

  公开号：US06355665B1

  公开（公告）日：2002-03-12

  A compound of the formula wherein R2 is an optionally substituted Cz to Cg alkylene or alkylene chain; R3 is C2 to C15 optionally substituted hydrocarbyl; X is a bond or —NR4—, wherein R4 is hydrogen or non-aromatic C1 to C5 optionally substituted hydrocarbyl, or aryl(C1 to C3)alkyl, or a pharmaceutically acceptable salt thereof. A method of modifing histamine activity in a patient comprising administering to said patient a pharmaceutical composition containing an effective amount of a compound of formula wherein R1 is selected from C1 to C6 alkyl, C1 to C6 alkoxy, C1 to C6 alkylthio, carboxy, carboxy(C1 to C6)alkyl, formyl, C1 to C6 alkylcarbonyl, C1 to C6 alkylcarbonylalkoxy, nitro, trihalomethyl, hydroxy, amino, C1 to C6 alkylcarbonylalkoxy, nitro, trihalomethyl, hydroxy, amino, C1 to C6 alkylamino, di(C1 to C6 alkyl)amino, aryl, C1 to C6 alkylaryl, halo, sulfamoyl and cyano; R2 is optionally substituted C2 to C20 hydrocarbylene, in which one or more hydrogen atoms may be replaced by halogen atoms and up to 6 carbon atoms may be replaced by oxygen or nitrogen atoms, R2 being in the form of an optionally substituted C2 to C8 alkylene or alkenylene chain; R3 is hydrogen or C1 to C15 optionally substituted hydrocarbyl; X is a bond or —NR4—; and a is from 0 to 2, or a pharmaceutically acceptable salt thereof.

  该化合物的化学式中，R2是一个可选取代的Cz到Cg烷基或烷基链；R3是C2到C15可选取代的烃基；X是一个键或-NR4-，其中R4是氢或非芳香C1到C5可选取代的烃基，或芳基(C1到C3)烷基，或其药学上可接受的盐。一种调节组胺在患者体内活性的方法，包括向该患者投予含有一定量该化合物的药物组合物，该化合物的化学式中，R1选自C1到C6烷基，C1到C6烷氧基，C1到C6烷硫基，羧基，羧基(C1到C6)烷基，甲酰基，C1到C6烷基羰基，C1到C6烷基羰基烷氧基，硝基，三卤甲基，羟基，氨基，C1到C6烷基羰基烷氧基，硝基，三卤甲基，羟基，氨基，C1到C6烷基氨基，二(C1到C6烷基)氨基，芳基，C1到C6烷基芳基，卤素，磺酰胺和氰基；R2是可选取代的C2到C20烃基，其中一个或多个氢原子可被卤素原子取代，最多6个碳原子可被氧原子或氮原子取代，R2以可选取代的C2到C8烷基或烯基链的形式存在；R3是氢或C1到C15可选取代的烃基；X是一个键或-NR4-；a为0到2，或其药学上可接受的盐。
• Fibrinogen receptor antagonists
  申请人：Merck & Co., Inc.

  公开号：US05648368A1

  公开（公告）日：1997-07-15

  Novel fibrinogen receptor antagonists of the formula: X--Y--Z--Aryl--A--B are provided in which the claimed compounds exhibit fibrinogen receptor antagonist activity, inhibit platelet aggregation and are therefore useful in modulating thrombus formation.

  提供了一种公式为X-Y-Z-Aryl-A-B的新型纤维蛋白原受体拮抗剂，所述化合物表现出纤维蛋白原受体拮抗活性，抑制血小板聚集，因此在调节血栓形成方面有用。
• Inhibitors of prenyl-protein transferase
  申请人：Merck & Co., Inc.

  公开号：US06441017B1

  公开（公告）日：2002-08-27

  The present invention is directed to macrocyclic compounds which inhibit prenyl-protein transferase (FTase) and the prenylation of the oncogene protein Ras. The invention is further directed to chemothera-peutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.

  本发明涉及一种宏环化合物，其抑制戊二烯蛋白转移酶（FTase）和致癌基因蛋白Ras的戊二烯化。本发明还涉及含有本发明化合物的化疗组合物以及抑制戊二烯蛋白转移酶和致癌基因蛋白Ras的方法。
• Facile Syntheses of Histamine- and Imidazole-4-propionic Acid–Derived Room-Temperature Ionic Liquids
  作者：Ravi Kant Dubey、Neeraj Kumar、Rahul Jain

  DOI：10.1080/00397911.2011.555053

  日期：2012.8.1

  We report synthesis of histamine- and imidazole-4-propionic acid-based ionic liquids containing a variety of alkyl and aryl groups placed at the two different positions of the constituent imidazole ring in convenient steps in good yields.